Dna Script Raises $165M In Oversubscribed Series C Financing To Accelerate Commercialization Of Enzymatic Dna Printing Platform
Amount Raised
$165 Million
Round Type
series c
Description
DNA Script, a pioneer in Enzymatic DNA Synthesis (EDS) and DNA printing on demand, today announced it has raised $165 million in a Series C financing led by Coatue Management and Catalio Capital Management, whose representatives have joined as Board observers. New investors Fidelity Management and Research, Columbia Threadneedle Investments, Arrowmark Partners, Farallon Capital and Moore Strategic Ventures joined the round. Existing investors Casdin Capital, LSP, Illumina Ventures, Bpifrance Large Venture Fund, Danaher Life Sciences, Agilent Technologies, M Ventures, Kurma Partners and Alexandria Venture Investments also participated in the round, bringing the total amount raised to date by the company to $280 million. The new funds will be used to accelerate expansion and commercialization of the company’s revolutionary SYNTAX Platform and broaden the portfolio of products powered by EDS.